A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination with Durvalumab (MEDI4736) or Tremelimumab in Patients with Advanced Solid Tumors
A study for patients with advanced solid tumors study drug durvalumab (MEDI4736)
Sponsor: Eli Lilly and Company
Enrolling: Male and Female Patients
IRB Number: AAAQ8659
U.S. Govt. ID: NCT02718911
Contact: Richard Carvajal MD: 212-305-7115 / rdc2150@cumc.columbia.edu
Additional Study Information: The primary purpose of this study is to determine a safe dose for the combinations of LY3022855 with durvalumab or LY3022855 with tremelimumab. This study will help answer the following research questions- What side effects may be experienced when taking LY3022885 with durvalumab ortremelimumab and how much LY302255, in combination with durvalumab or tremelimumab, should be given to the research subjects/participants diagnosed with advanced solid tumors.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Have you been diagnosed with advanced solid tumors? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Richard Carvajal MD
rdc2150@cumc.columbia.edu
212-305-7115
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE